5.06

3.16% +0.15

uniQure N.V. (QURE)

Overview News Price History Option Chain Financials Discussions Forecast

uniQure N.V. stock is currently priced at $5.06, with a 24-hour trading volume of 311.12K. It has seen a +3.16% increased in the last 24 hours and a +6.86% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.95 pivot point. If it approaches the $5.06 resistance level, significant changes may occur.

Previous Close:

$4.91

Open:

$5.04

24h Volume:

311.12K

Market Cap:

$244.69M

Revenue:

$15.84M

Net Income/Loss:

$-308.48M

P/E Ratio:

-1.2843

EPS:

-3.94

Net Cash Flow:

$-153.08M

1W Performance:

+3.58%

1M Performance:

+6.86%

6M Performance:

-23.89%

1Y Performance:

-76.62%

1D Range:

$5.02

$5.175

52W Range:

$4.25

$21.88

uniQure N.V. Stock (QURE) Company Profile

Name

uniQure N.V.

Sector

Healthcare (1213)

Industry

Biotechnology (696)

Phone

31 20 240 6000

Address

Paasheuvelweg 25a, Amsterdam

Employee

202

Twitter

@uniQure_NV

Next Earnings Date

2024-05-15

Latest SEC Filings

QURE's Discussions on Twitter

uniQure N.V. Stock (QURE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-22	Upgrade	UBS	Neutral → Buy
Jun-15-21	Initiated	BTIG Research	Buy
May-21-21	Initiated	UBS	Neutral
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-01-21	Upgrade	Mizuho	Neutral → Buy
Jan-07-21	Upgrade	Guggenheim	Neutral → Buy
Nov-24-20	Initiated	H.C. Wainwright	Buy
Nov-11-20	Initiated	Berenberg	Buy
Nov-09-20	Initiated	Jefferies	Buy
Nov-04-20	Initiated	Cantor Fitzgerald	Overweight
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Aug-25-20	Initiated	Raymond James	Strong Buy
Jul-31-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jun-25-20	Downgrade	Mizuho	Buy → Neutral
Jun-25-20	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-25-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-03-19	Initiated	Cowen	Outperform
Dec-03-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	Credit Suisse	Outperform
Oct-11-19	Initiated	Stifel	Buy
Sep-25-19	Initiated	Bernstein	Outperform
Sep-12-19	Initiated	Mizuho	Buy
Jul-30-19	Downgrade	Guggenheim	Buy → Neutral
Jul-08-19	Reiterated	Cantor Fitzgerald	Overweight
Apr-12-19	Initiated	Piper Jaffray	Overweight
Mar-29-19	Initiated	Robert W. Baird	Outperform

View All

uniQure N.V. Stock (QURE) Latest News

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire Inc.

AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

Benzinga

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire Inc.

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

uniQure N.V. Stock (QURE) Financials Data

uniQure N.V. (QURE) Revenue 2024

QURE reported a revenue (TTM) of $15.84 million for the quarter ending December 31, 2023, a -85.12% decline year-over-year.

uniQure N.V. (QURE) Net Income 2024

QURE net income (TTM) was -$308.48 million for the quarter ending December 31, 2023, a -143.30% decrease year-over-year.

uniQure N.V. (QURE) Cash Flow 2024

QURE recorded a free cash flow (TTM) of -$153.08 million for the quarter ending December 31, 2023, a +5.94% increase year-over-year.

uniQure N.V. (QURE) Earnings per Share 2024

QURE earnings per share (TTM) was -$6.48 for the quarter ending December 31, 2023, a -139.11% decline year-over-year.

uniQure N.V. Stock (QURE) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
KLEMT CHRISTIAN	Chief Financial Officer	Feb 26 '24	Sale	6.38	15,906	101,480	116,948
CALOZ PIERRE	Chief Operating Officer	Feb 26 '24	Sale	6.47	9,455	61,174	85,643
Dolmetsch Ricardo	President, R&D	Sep 18 '23	Sale	7.46	5,841	43,574	163,404
CALOZ PIERRE	Chief Operating Officer	Jul 10 '23	Sale	11.36	15,117	171,729	95,098
Gut Robert	Director	Jun 16 '23	Sale	18.88	3,228	60,945	47,669
CALOZ PIERRE	Chief Operating Officer	Jun 16 '23	Sale	18.80	2,920	54,896	110,215
Soteropoulos Paula	Director	Jun 16 '23	Sale	18.99	2,275	43,202	22,423
Balachandran Madhavan	Director	Jun 16 '23	Sale	18.91	2,283	43,172	25,990
Jacques Rachelle Suzanne	Director	Jun 16 '23	Sale	18.76	2,301	43,167	16,629
Meek David D.	Director	Jun 16 '23	Sale	18.85	2,290	43,166	22,481

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.